EVAX

Evaxion Biotech AS

EVAX, USA

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

https://evaxion.ai

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
EVAX
stock
EVAX

S P Trends: Will EVAX stock gain from strong economy - Earnings Trend Report & Real-Time Chart Breakout Alerts moha.gov.vn

Read more →
EVAX
stock
EVAX

Evaxion Biotech stock holds Buy rating at H.C. Wainwright after ASH data Investing.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$14.175

Analyst Picks

Strong Buy

1

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.41

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

27.82 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very High

15.53 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Low

0.79

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 1.91% of the total shares of Evaxion Biotech AS

1.

Ikarian Capital, LLC

(1.2665%)

since

2025/06/30

2.

BOOTHBAY FUND MANAGEMENT, LLC

(0.3756%)

since

2025/06/30

3.

Rhumbline Advisers

(0.1494%)

since

2025/06/30

4.

GAMMA Investing LLC

(0.0553%)

since

2025/06/30

5.

UBS Group AG

(0.0323%)

since

2025/06/30

6.

Beacon Capital Management, LLC

(0.0154%)

since

2025/06/30

7.

Fidelity Nasdaq Composite Index

(0.0098%)

since

2025/07/31

8.

SBI Securities Co Ltd

(0.001%)

since

2025/06/30

9.

Advisor Group Holdings, Inc.

(0.0004%)

since

2025/06/30

10.

SouthState Bank Corp

(0%)

since

2025/03/31

11.

Millennium Management LLC

(0%)

since

2025/03/31

12.

JPMorgan Chase & Co

(0%)

since

2025/03/31

13.

Armistice Capital, LLC

(0%)

since

2025/03/31

14.

XTX Topco Ltd

(0%)

since

2025/06/30

15.

Invst LLC

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0.01

EPS Estimate

-0.01

EPS Difference

0.02

Surprise Percent

200%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7.5)
Defensive
Moderately Defensive(4.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Wide Moat Company(9)
GARP
Fair GARP(5.5)
Growth
Moderate Growth(4.5)
Momentum
Moderate Momentum(5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(7)
Value
Undervalued(9.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.